Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone

Vesicular monoamine transporter 2 (VMAT2) is responsible for packing monoamine neurotransmitters into synaptic vesicles for storage and subsequent neurotransmission. VMAT2 inhibitors are approved for symptomatic treatment of tardive dyskinesia and Huntington’s chorea, but despite being much-studied...

Descripción completa

Detalles Bibliográficos
Autores principales: Støve, Svein Isungset, Skjevik, Åge Aleksander, Teigen, Knut, Martinez, Aurora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684503/
https://www.ncbi.nlm.nih.gov/pubmed/36418492
http://dx.doi.org/10.1038/s42003-022-04121-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684503/
https://www.ncbi.nlm.nih.gov/pubmed/36418492
http://dx.doi.org/10.1038/s42003-022-04121-1

Ejemplares similares